{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:20:28Z","timestamp":1790022028555,"version":"4.0.1"},"reference-count":45,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>mTOR inhibitors such as everolimus and BEZ235 have demonstrated efficacy in pancreatic neuroendocrine tumors (PanNET) at the cost of severe side effects, and no biomarker currently predicts response. To identify molecular pathways of resistance, precision-cut slices of 17 fresh well-differentiated PanNET were cultured with everolimus or BEZ235 for 2 days and immunostained with cleaved caspase-3 and mTOR pathway markers. Transcriptomes of sensitive and resistant tumors were compared, and candidate pathways validated by immunohistochemistry. The predictive value of key proteins was then assessed in 26 PanNET patients treated with everolimus. mTOR inhibitors induced significant apoptosis and loss of pS6 and p4EBP1 in tumor slices, with 6\/17 tumors considered sensitive. Transcriptomic analysis revealed that sensitive tumors displayed a mitochondrial-based metabolism, whereas resistant tumors exhibited a hypoxic and glycolytic profile, confirmed by high expression of CAIX, GLUT1, ATP5O, and mtTFA. Necrosis was absent and microvessel density similar in both groups, suggesting a pseudohypoxic metabolism in resistant tumors. High expression of CAIX and LDHA, two markers of pseudohypoxia\/glycolysis, was associated with shorter progression-free survival in patients treated with everolimus. This study demonstrates that tissue culture can effectively assess drug response in PanNET and identifies a pseudohypoxic\/glycolytic profile as a determinant of resistance to mTOR inhibition, detectable by immunohistochemistry and potentially noninvasively by 18F-FDG PET-CT.<\/jats:p>","DOI":"10.1530\/erc-24-0331","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:40:15Z","timestamp":1758040815000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of metabolic state on PanNET response to mTOR inhibitors"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-3865","authenticated-orcid":true,"given":"J\u00e9r\u00f4me","family":"Cros","sequence":"first","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Bucau","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-4657","authenticated-orcid":true,"given":"Matthieu","family":"Tihy","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Pancreatology Department, Beaujon Hospital, AP-HP 4 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bourgoin","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Chassac","sequence":"additional","affiliation":[{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Sauvanet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Hepatobiliary and Pancreatic Surgery Department, Beaujon Hospital, AP-HP 5 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safi","family":"Dokmak","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Hepatobiliary and Pancreatic Surgery Department, Beaujon Hospital, AP-HP 5 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Dioguardi Burgio","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Radiology Department, Beaujon Hospital, AP-HP 6 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hentic","sequence":"additional","affiliation":[{"name":"Pancreatology Department, Beaujon Hospital, AP-HP 4 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pancreatology Department, Beaujon Hospital, AP-HP 4 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-9189","authenticated-orcid":true,"given":"Louis","family":"de Mestier","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pancreatology Department, Beaujon Hospital, AP-HP 4 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinciane","family":"Rebours","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pancreatology Department, Beaujon Hospital, AP-HP 4 , ,","place":["Clichy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Couvelard","sequence":"additional","affiliation":[{"name":"Inserm U1149-CRI, Beaujon Hospital 1 , ,","place":["Clichy, France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, FHU MOSAIC 2 , ,","place":["Clichy, France"]},{"name":"Pathology Department Beaujon-Bichat, AP-HP 3 , ,","place":["Clichy-Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2026070905464598700_bib1","volume-title":"WHO Classification of Tumours","author":"World Health Organization","year":"2019","edition":"5th edn, vol 1"},{"key":"2026070905464598700_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070905464598700_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905464598700_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2026070905464598700_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905464598700_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070905464598700_bib7","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2012.46.6946","article-title":"Prognostic significance of MTOR pathway component expression in neuroendocrine tumors","volume":"26","author":"Qian","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070905464598700_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026070905464598700_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrgastro.2012.9","article-title":"Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy","volume":"9","author":"de Wilde","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070905464598700_bib10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"2026070905464598700_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","article-title":"The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells","volume":"85","author":"Zitzmann","year":"2007","journal-title":"Neuroendocrinology"},{"key":"2026070905464598700_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2026070905464598700_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/ERC-13-0042","article-title":"mTOR, p70S6K, AKT and ERK1\/2 levels predict sensitivity to mTOR and PI3K\/mTOR inhibitors in human bronchial carcinoids","volume":"20","author":"Gagliano","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026070905464598700_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-013-0792-4","article-title":"Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors","volume":"31","author":"Nishikawa","year":"2014","journal-title":"Med Oncol"},{"key":"2026070905464598700_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cc.11.3.19096","article-title":"mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors","volume":"11","author":"Zhang","year":"2012","journal-title":"Cell Cycle Georget Tex"},{"key":"2026070905464598700_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7150\/thno.7851","article-title":"PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms","volume":"4","author":"Briest","year":"2014","journal-title":"Theranostics"},{"key":"2026070905464598700_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MPA.0b013e31827ae993","article-title":"Animal models and cell lines of pancreatic neuronimal models and cell lines of pancreatic neuroendocrine tumors","volume":"42","author":"Babu","year":"2013","journal-title":"Pancreas"},{"key":"2026070905464598700_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gni179","article-title":"Evolving gene\/transcript definitions significantly alter the interpretation of GeneChip data","volume":"33","author":"Dai","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"2026070905464598700_bib18","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905464598700_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2006.04.009","article-title":"Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro","volume":"45","author":"van de Bovenkamp","year":"2006","journal-title":"J Hepatol"},{"key":"2026070905464598700_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/toxsci\/kfh285","article-title":"Organ slice viability extended for pathway characterization: an in vitro model to investigate fibrosis","volume":"82","author":"Vickers","year":"2004","journal-title":"Toxicol Sci"},{"key":"2026070905464598700_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2174\/1568007054546108","article-title":"Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair","volume":"4","author":"Noraberg","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"2026070905464598700_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104826","article-title":"Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing","volume":"97","author":"Jagatia","year":"2023","journal-title":"EBioMedicine"},{"key":"2026070905464598700_bib23","article-title":"A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease","volume":"5","author":"Hammoutene","year":"2023","journal-title":"JHEP Rep"},{"key":"2026070905464598700_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076229","article-title":"Hypoxia pathways and cellular stress activate pancreatic stellate cells: development of an organotypic culture model of thick slices of normal human pancreas","volume":"8","author":"Rebours","year":"2013","journal-title":"PLoS One"},{"key":"2026070905464598700_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.909180","article-title":"Human immunocompetent model of neuroendocrine liver metastases recapitulates patient-specific tumour microenvironment","volume":"13","author":"Doornebal","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070905464598700_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1478-3231.2006.01268.x","article-title":"Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma","volume":"26","author":"Kern","year":"2006","journal-title":"Liver Int"},{"key":"2026070905464598700_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2007.11.039","article-title":"Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model","volume":"108","author":"Kendrick","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2026070905464598700_bib28","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/IGC.0b013e3181a2a003","article-title":"Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model","volume":"19","author":"Frederick","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2026070905464598700_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/CAD.0b013e32833d1a11","article-title":"Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model","volume":"21","author":"Dean","year":"2010","journal-title":"Anti Cancer Drugs"},{"key":"2026070905464598700_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00441-013-1608-8","article-title":"Breast cancer tissue slices as a model for evaluation of response to rapamycin","volume":"352","author":"Grosso","year":"2013","journal-title":"Cell Tissue Res"},{"key":"2026070905464598700_bib31","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/0008-5472.CAN-12-2545","article-title":"Inhibition of rapamycin-induced AKT activation Elicits differential antitumor response in head and neck cancers","volume":"73","author":"Radhakrishnan","year":"2013","journal-title":"Cancer Res"},{"key":"2026070905464598700_bib32","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1073\/pnas.0907676107","article-title":"Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors","volume":"107","author":"Vaira","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905464598700_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tox.2006.03.020","article-title":"Stability of cytochromes P450 and phase II conjugation systems in precision-cut rat lung slices cultured up to 72 h","volume":"224","author":"Umachandran","year":"2006","journal-title":"Toxicology"},{"key":"2026070905464598700_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41698-024-00549-2","article-title":"Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies","volume":"8","author":"April-Monn","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026070905464598700_bib35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.ccell.2023.11.007","article-title":"Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites","volume":"41","author":"Dayton","year":"2023","journal-title":"Cancer Cell"},{"key":"2026070905464598700_bib36","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res"},{"key":"2026070905464598700_bib37","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070905464598700_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2010.02.018","article-title":"Compensatory activation of Akt in response to mTOR and Raf inhibitors \u2013 a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease","volume":"295","author":"Zitzmann","year":"2010","journal-title":"Cancer Lett"},{"key":"2026070905464598700_bib39","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2026070905464598700_bib40","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2026070905464598700_bib41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000480239","article-title":"18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation","volume":"106","author":"Bucau","year":"2018","journal-title":"Neuroendocrinology"},{"key":"2026070905464598700_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.freeradbiomed.2016.04.010","article-title":"Mitochondrial translation factors reflect coordination between organelles and cytoplasmic translation via mTOR signaling: implication in disease","volume":"100","author":"Cao","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"2026070905464598700_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-017-3275-z","article-title":"One-month assessment of renal cell carcinoma treated by everolimus using FDG PET\/CT predicts progression-free and overall survival","volume":"79","author":"Ito","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070905464598700_bib44","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00428-018-2353-x","article-title":"Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival","volume":"472","author":"Kim","year":"2018","journal-title":"Virchows Arch"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/9\/ERC-24-0331.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/9\/ERC-24-0331.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0331\/145410\/erc-24-0331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0331\/145410\/erc-24-0331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:47:00Z","timestamp":1783590420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/9\/e240331\/25995\/Predictive-value-of-metabolic-state-on-PanNET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0331","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"e240331"}}